宫颈癌的分子靶向药物治疗

doi:10.3760/cma.j.issn.1673422X.2016.07.018

摘要/Abstract

摘要： 晚期及复发性宫颈癌预后差，缺乏有效的治疗手段。随着分子生物学的发展，在局部晚期宫颈癌患者的治疗中靶向治疗药物不断涌现，包括抑制人乳头瘤病毒、靶向抑制肿瘤血管生成、表皮生长因子、哺乳动物雷帕霉素靶蛋白、环氧合酶2、鸡肉瘤病毒基因、蛋白酶体抑制剂、DNA甲基化等。随着新型分子靶向治疗的不断发展，可能会发现更有效的宫颈癌疗法，为宫颈癌的个体化治疗开辟新的途径。

关键词: 宫颈肿瘤, 药物疗法, 分子靶向治疗

Abstract: Advanced and recurrent cervical cancer has a poor prognosis and few effective therapeutic option. With the development of molecular biology, the targeted drugs for patients with locally advanced cervical cancer continuously appear, such as inhibiting human papillomavirus, targeting angiogenesis, epidermal growth factor receptor, mammalian target of rapamycin, cyclooxygenase2, sarcoma gene, proteasome inhibitor, DNA methylation, etc. With the development of new molecular targeted therapy, more effective or even treatment measures of cervical cancer might be found, which can provid a new approach for the individualized treatment of cervical cancer.

Key words: Uterine cervical neoplasms, Drug therapy, Molecular targeted therapy

周春霞, 周雪. 宫颈癌的分子靶向药物治疗[J]. 国际肿瘤学杂志, 2016, 43(7): 548-551.

ZHOU Chun-Xia, ZHOU Xue. Molecular targeted drug therapy of cervical cancer[J]. Journal of International Oncology, 2016, 43(7): 548-551.

参考文献

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87108. DOI: 10.3322/caac.21262. ［2］ Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer［J］. N Engl J Med, 2014, 370(8): 734743. DOI: 10.1056/NEJMoa1309748. ［3］ Mountzios G, Soultati A, Pectasides D, et al. Developments in the systemic treatment of metastatic cervical cancer［J］. Cancer Treat Rev, 2013, 39(5): 430443. DOI: 10.1016/j.ctrv.2012.05.009. ［4］ Kim MS , Bak Y, Park YS, et al. Wogonin induces apoptosis by suppressing E6 and E7 expressions and activating intrinsic signaling pathways in HPV16 cervical cancer cells［J］. Cell Biol Toxicol, 2013, 29(4): 259272. DOI: 10.1007/s1056501392514. ［5］ Zhou Y, Zhang C, Liang W. Development of RNAi technology for targeted therapya track of siRNA based agents to RNAi therapeutics［J］. J Control Release, 2014, 193: 270281. DOI: 10.1016/j.jconrel.2014.04.044. ［6］ Zhao CY, Szekely L, Bao W, et al. Rescue of p53 function by smallmolecule RITA in cervical carcinoma by blocking E6mediated degradation［J］. Cancer Res, 2010, 70(8): 33723381. DOI: 10.1158/00085472.CAN092787. ［7］ Van Pachterbeke C, Bucella D, Rozenberg S, et al. Topical treatment of CIN2+ by cidofovir: results of a phase Ⅱ, doubleblind, prospective, placebocontrolled study［J］. Gynecol Oncol, 2009, 115(1): 6974. DOI: 10.1016/j.ygyno.2009.06.042. ［8］ Bodily JM, Mehta KP, Laimins LA. Human papillomavirus E7 enhances hypoxiainducible factor 1mediated transcription by inhibiting binding of histone deacetylases［J］. Cancer Res, 2011, 71(3): 11871195. DOI: 10.1158/00085472.CAN102626. ［9］ Alvarez EA, Brady WE, Walker JL, et al. Phase Ⅱ trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study［J］. Gynecol Oncol, 2013, 129(1): 2227. DOI: 10.1016/j.ygyno.2012.12.022. ［10］ Friedlander ML. Commentary on the clinical trial reported by: Tewari KS, Sill M, Long Ⅲ HJ, et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase Ⅲ randomized trial of the Gynecologic Oncology Group［J］. J Clin Oncol, 2014, 3(1): 6. DOI: 10.3978/j.issn.23043865.2013.11.01. ［11］ Zighelboim I, Wright JD, Gao F, et al. Multicenter phase Ⅱ trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer［J］. Gynecol Oncol, 2013, 130(1): 6468. DOI: 10.1016/j.ygyno.2013.04.009. ［12］ Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPTTIE2 pathway in malignancy［J］. Nat Rev Cancer, 2010, 10(8): 575585. DOI: 10.1038/nrc2894. ［13］ Mackay HJ, Tinker A, Winquist E, et al. A phase Ⅱ study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184［J］. Gynecol Oncol, 2010, 116(2): 163167. DOI: 10.1016/j.ygyno.2009.08.012. ［14］ Monk BJ, Pandite LN. Survival data from a phase Ⅱ, openlabel study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer［J］. J Clin Oncol, 2011, 29(36): 4845. DOI: 10.1200/JCO.2011.38.8777. ［15］ Candelaria M, AriasBonfill D, ChávezBlanco A, et al. Lack in efficacy for imatinib mesylate as secondline treatment of recurrent or metastatic cervical cancer expressing plateletderived growth factor receptor alpha［J］. Int J Gynecol Cancer, 2009, 19(9): 16321637. DOI: 10.1111/IGC.0b013e3181a80bb5. ［16］ Woodworth CD, Diefendorf LP, Jette DF, et al. Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16［J］. Virology, 2011, 421(1): 1927. DOI: 10.1016/j.virol.2011.09.014. ［17］ NogueiraRodrigues A, Moralez G, Grazziotin R, et al. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer［J］. Cancer, 2014, 120(8): 11871193. DOI: 10.1002/cncr.28471. ［18］ Kurtz JE, HardyBessard AC, Deslandres M, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase Ⅱ GINECO trial［J］. Gynecol Oncol, 2009, 113(1): 1620. DOI: 10.1016/j.ygyno.2008.12.040. ［19］ Tornesello ML, Annunziata C, Buonaguro L, et al. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and highgrade intraepithelial neoplasia of the cervix［J］. J Transl Med, 2014, 12: 255. DOI: 10.1186/s1296701402555. ［20］ Tinker AV, Ellard S, Welch S, et al. Phase Ⅱ study of temsirolimus (CCI779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)［J］. Gynecol Oncol, 2013, 130(2): 269274. DOI: 10.1016/j.ygyno.2013.05.008. ［21］ Doll CM, Winter K, Gaffney DK, et al. COX2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128［J］. Int J Gynecol Cancer, 2013, 23(1): 176183. DOI: 10.1097/IGC.0b013e3182791efc. ［22］ Grabosch SM, Shariff OM, Wulff JL, et al. Nonsteroidal antiinflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia［J］. Cochrane Database Syst Rev, 2014, 4: CD004121. DOI: 10.1002/14651858.CD004121.pub3. ［23］ Szalmás A, Gyngysi E, Ferenczi A, et al. Activation of Src, Fyn and Yes nonreceptor tyrosine kinases in keratinocytes expressing human papillomavirus (HPV) type 16 E7 oncoprotein［J］. Virol J, 2013, 10: 79. DOI: 10.1186/1743422X1079. ［24］ Stern PL, van der Burg SH, Hampson IN, et al. Therapy of human papillomavirusrelated disease［J］. Vaccine, 2012, 30 Suppl 5: F7182. DOI: 10.1016/j.vaccine.2012.05.091. ［25］ Miyamoto Y, Nakagawa S, WadaHiraike O, et al. Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines［J］. Oncol Rep, 2013, 29(1): 5157. DOI: 10.3892/or.2012.2072. ［26］ Masuda K, Banno K, Yanokura M, et al. Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells［J］. Oncol Rep, 2012, 28(4): 11461152. DOI: 10.3892/or.2012.1912. ［27］ Tanaka T, Bai T, Toujima S, et al. Demethylation restores SN38 sensitivity in cells with acquired resistance to SN38 derived from human cervical squamous cancer cells［J］. Oncol Rep, 2012, 27(4): 12921298. DOI: 10.3892/or.2012.1628. ［28］ Xing J, Wang H, Xu S, et al. Sensitization of suberoylanilide hydroxamic acid (SAHA) on chemoradiation for human cervical cancer cells and its mechanism［J］. Eur J Gynaecol Oncol, 2015, 36(2): 117122. ［29］ Tsai C, Leslie JS, FrankoTobin LG, et al. Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptortargeted cancer chemotherapeutic via activating somatostatin receptor type Ⅱ［J］. Arch Gynecol Obstet, 2013, 288(2): 393400. DOI: 10.1007/s0040401327627. ［30］ Shunkwiler L, Ferris G, Kunos C. Inhibition of poly(ADPRibose) polymerase enhances radiochemosensitivity in cancers proficient in DNA doublestrand break repair［J］. Int J Mol Sci, 2013, 14(2): 37733785. DOI: 10.3390/ijms14023773.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[4]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[5]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[6]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[7]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[8]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[9]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[10]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[11]	李开春, 丁昌利, 于文艳. 安罗替尼联合特瑞普利单抗治疗晚期肺肉瘤样癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 511-512.
[12]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[13]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[14]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[15]	刘利, 朱思齐, 孙梦颖, 何敬东. PARP抑制剂在小细胞肺癌靶向治疗中的进展[J]. 国际肿瘤学杂志, 2023, 50(6): 368-372.